Alzheimer's Disease Therapeutics
•18 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (18)
%
| Company | Market Cap | Price |
|---|---|---|
|
Direct product: LEQEMBI is Biogen's monoclonal antibody therapy for Alzheimer's disease.
|
$21.48B |
$146.57
-2.29%
|
|
ARO-MAPT program targets Alzheimer's disease, aligning with Alzheimer's therapeutics.
|
$4.89B |
$35.41
-1.64%
|
|
The pipeline includes ACP-204 targeting Alzheimer's disease psychosis and Lewy body dementia psychosis, aligning with Alzheimer's disease therapeutics.
|
$3.52B |
$21.05
-0.94%
|
|
Positive Alzheimer's biomarker data suggests potential development as an Alzheimer's Disease Therapeutics.
|
$3.42B |
$37.05
+10.86%
|
|
Lead Alzheimer's disease therapeutic (blarcamesine) directly aligns with Alzheimer's Disease Therapeutics.
|
$791.40M |
$9.27
-1.80%
|
|
Direct focus on Alzheimer's disease therapeutics via PRX012 (anti-amyloid beta antibody) as a wholly-owned program.
|
$540.96M |
$10.05
-2.80%
|
|
Pipeline includes Alzheimer's disease therapeutic exploration (VG-3927 planned Phase 2 in AD).
|
$375.71M |
$8.05
|
|
AC Immune targets Alzheimer's disease via anti-Abeta and anti-Tau active immunotherapies, aligning with Alzheimer's Disease Therapeutics.
|
$354.43M |
$3.55
+0.28%
|
|
Exploratory efficacy in Alzheimer's Disease indicates the company’s pipeline directly targets AD therapeutics.
|
$210.30M |
$2.04
-5.56%
|
|
Direct Alzheimer's disease therapeutics product line (ZUNVEYL) targets mild-to-moderate Alzheimer's disease.
|
$112.46M |
$7.02
-7.99%
|
|
Company is advancing an Alzheimer's disease therapy; fits an Alzheimer’s Disease Therapeutics investable theme.
|
$104.79M |
$1.73
-3.35%
|
|
COYA is developing Alzheimer's disease therapeutics (LD IL-2 and related candidates), supported by AD biomarker data.
|
$101.52M |
$6.07
-3.04%
|
|
Alzheimer's Disease Therapeutics is a specific target within the therapeutic pipeline, even if progress is paused.
|
$50.65M |
$1.53
-3.77%
|
|
The lead program targets Alzheimer's disease and reports cognition-related efficacy, aligning with Alzheimer's Disease Therapeutics.
|
$43.26M |
$2.22
-0.45%
|
|
IGC-AD1 is the lead Alzheimer’s disease therapeutic candidate in Phase 2, directly mapped to Alzheimer’s Disease Therapeutics.
|
$33.48M |
$0.40
-4.29%
|
|
HT-ALZ targets Alzheimer's disease with neuroinflammatory considerations, mapping to Alzheimer's Disease Therapeutics.
|
$20.87M |
$1.58
-5.39%
|
|
Company aims to develop Alzheimer's disease therapeutics (AL001 and ALZN002) and thus fits Alzheimer's Disease Therapeutics.
|
$6.31M |
$2.18
-5.63%
|
|
SPC-14 targets Alzheimer's disease, placing the company in Alzheimer's Disease Therapeutics.
|
$2.52M |
$0.56
-16.31%
|
Loading industry metrics...
Loading comparison data...
